Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, March 1, 2026

NMN improves high-fat-diet-induced myocardial damage of aging mice through Sirt3/PINK1/Parkin signaling pathway

 Didn't your competent? doctor prescribe NMN years ago? NO? So fucking incompetence reigned and your doctor is still employed?

NMN improves high-fat-diet-induced myocardial damage of aging mice through Sirt3/PINK1/Parkin signaling pathway


https://doi.org/10.1016/j.tjnut.2026.101435Get rights and content

Abstract

Background

Long-term high-fat diet (HFD) consumption is associated with the development of metabolic cardiomyopathy and contributes to accelerated cardiac aging. Nicotinamide mononucleotide (NMN), a key NAD+ precursor, has shown promise in ameliorating age-related cardiac decline, but its mechanisms are not fully understood.

Methods

14-month-old male C57BL/6J mice were divided into three groups: normal-diet (ND) group, high-fat diet (HFD) group and HFD+NMN group. NMN was added to their drinking water at a dose of 400 mg/kg for 7 months. Cardiac tissues were collected and analyzed using hematoxylin and eosin (H&E) and Masson's trichrome staining, Western blotting, Quantitative Real-Time PCR, and immunohistochemistry. In vitro, H9c2 cardiomyocytes were exposed to palmitic acid (PA) to establish a lipotoxicity model, and the effects of NMN on cell viability and autophagy flux were assessed via MTT assay and mRFP-GFP-LC3 adenoviral transfection.

Results

Compared to HFD group, NMN treatment significantly reduced the heart index, ameliorated myocardial fibrosis, and decreased the expression levels of senescence-associated secretory phenotype (SASP) markers (Serpine1, MMP3, CXCL-1, CXCL-10, P16; P<0.05), as well as senescence markers (P21 and β-gal; P<0.01), pro-inflammatory cytokines (IL-1β and TNF-α; P<0.05) and apoptotic indicators (Bax/Bcl-2 ratio, cleaved caspase-3; P<0.01). Conversely, NMN treatment upregulated the levels of anti-inflammatory factor IL-10 (P<0.01) in the cardiac tissue. Furthermore, NMN treatment increased protein levels of Sirt3, PINK1 and Parkin (P<0.01), and enhanced autophagy-lysosomal markers including LC3-II/LC3-I ratio and TFEB (P<0.05), alongside decreased p62 level (P<0.01) in cardiac tissue. In H9c2 cardiomyocytes, NMN treatment significantly attenuated PA-induced cytotoxicity (P<0.01) and enhanced PA-induced the impaired autophagy flux. Notably, these protective effects were abolished by co-treatment with 3-TYP, a selective Sirt3 inhibitor.

Conclusion

NMN alleviates HFD-induced myocardial damage of aging mice by activating the Sirt3/PINK1/Parkin signaling pathway, enhancing autophagy-lysosomal function. These findings indicate that NMN is a promising therapeutic candidate for the treatment of metabolic cardiomyopathy.

No comments:

Post a Comment